ADNI is governed by a Steering Committee comprised of the PI, all funded Core leaders, all site PIs, representatives of the NIH and FDA, and representatives of the companies contributing funding (observers only). Together, with the Executive Committee and the Industry Scientific Advisory Board, these bodies ensure that the ADNI project adheres to the study design and methodology laid out in the grant submission.
Achieving the aims of the ADNI study would not be possible without the collaboration of hundreds of researchers, staff, industry advisors and research volunteers.
Learn more about the ADNI governance:
The National Institute on Aging (NIA), part of the National Institutes of Health, leads the federal government’s effort by conducting and supporting research on the biomedical, social and behavioral issues of older people. The NIA provides information on age-related cognitive change and neurodegenerative disease specifically through the Alzheimer’s Disease Education and Referral (ADEAR) Center.
ADNI Steering Committee Meetings take place annually in the Spring. Get the presentations.
The day-to-day operations of the initiative are directed by the Principle Investigator, Michael W. Weiner, and the Executive Committee which consists of the PIs of the Center and Cores.
Private Partner Scientific Board
The ADNI Private Partner Scientific Board (PPSB), convened by the Foundation for the National Institutes of Health, serves as a forum for open dialogue as it relates to the project’s progress and new trends in research and development as it relates to the field of Alzheimer’s disease. If you have any questions about the PPSB or how to become a member, please contact Julie Wolf-Rodda at firstname.lastname@example.org. Current PPSB partners include:
|Alzheimer’s AssociationAlzheimer’s Drug Discovery Foundation
Amorfix Life Sciences Ltd.
Canadian Institutes of Health Research
Eli Lilly and Company
F. Hoffman-La Roche Ltd.
|IXICO Ltd.Institut de Recherches Internationales Servier
Janssen Alzheimer Immunotherapy
Johnson & Johnson
Merck and Co.
Novartis Pharmaceuticals Corporation